×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PTCT – ptc therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PTCT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
08:19 am
ptct
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results [Yahoo! Finance]
4/17
08:00 am
ptct
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
Low
Report
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
3/31
04:17 pm
ptct
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies [Yahoo! Finance]
Medium
Report
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies [Yahoo! Finance]
3/31
10:45 am
ptct
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at JPMorgan Chase & Co. from $78.00 to $75.00. They now have an "overweight" rating on the stock.
Medium
Report
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target lowered by analysts at JPMorgan Chase & Co. from $78.00 to $75.00. They now have an "overweight" rating on the stock.
3/28
04:30 pm
ptct
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28
09:00 am
ptct
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
Low
Report
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
3/24
10:58 am
ptct
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion [Yahoo! Finance]
Low
Report
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion [Yahoo! Finance]
3/20
08:00 am
ptct
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
Medium
Report
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/17
09:36 am
ptct
Form SCHEDULE 13G/A PTC THERAPEUTICS, INC. Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G/A PTC THERAPEUTICS, INC. Filed by: BlackRock, Inc.
4/4
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Apr 02 Filed by: Golden Lee Scott
Low
Report
Form 4 PTC THERAPEUTICS, INC. For: Apr 02 Filed by: Golden Lee Scott
4/2
03:24 pm
ptct
Form 144 PTC THERAPEUTICS, INC. Filed by: Golden Lee Scott
Low
Report
Form 144 PTC THERAPEUTICS, INC. Filed by: Golden Lee Scott
3/28
11:12 am
ptct
Form 8-K PTC THERAPEUTICS, INC. For: Mar 28
Low
Report
Form 8-K PTC THERAPEUTICS, INC. For: Mar 28
3/18
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Mar 14 Filed by: Pauwels Eric
Low
Report
Form 4 PTC THERAPEUTICS, INC. For: Mar 14 Filed by: Pauwels Eric
3/17
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Mar 13 Filed by: Okey Stephanie
Medium
Report
Form 4 PTC THERAPEUTICS, INC. For: Mar 13 Filed by: Okey Stephanie
3/17
04:48 pm
ptct
Form 144 PTC THERAPEUTICS, INC. Filed by: Pauwels Eric
Low
Report
Form 144 PTC THERAPEUTICS, INC. Filed by: Pauwels Eric
3/14
05:20 pm
ptct
Form 4 PTC THERAPEUTICS, INC. For: Mar 12 Filed by: Boulding Mark Elliott
Medium
Report
Form 4 PTC THERAPEUTICS, INC. For: Mar 12 Filed by: Boulding Mark Elliott
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/6
Biogen Stock Rockets On Key Patent Win — Is It Time To Buy Shares? [Investor's Business Daily]
10.5%
3/4 PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "hold" rating re-affirmed by analysts at Barclays PLC. They now have a $51.00 price target on the stock. 9.3%
10/29 PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.9%
5/8 PTC Therapeutics to Participate at Upcoming Investor Conferences 7.9%
3/18 Form 4 PTC THERAPEUTICS, INC. For: Mar 16 Filed by: SCHMERTZLER MICHAEL 6.2%
6/17 PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 5.9%
3/18 Form SEC STAFF LETTER PTC THERAPEUTICS, INC. 5.7%
10/2 Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress 5.6%
3/30 PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 5.5%
4/17 PTC Therapeutics Announces New Leadership Appointments 4.8%
3/4 PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "hold" rating re-affirmed by analysts at Barclays PLC. They now have a $51.00 price target on the stock. 9.3%
10/29 PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 7.9%
5/8 PTC Therapeutics to Participate at Upcoming Investor Conferences 7.9%
3/18 Form 4 PTC THERAPEUTICS, INC. For: Mar 16 Filed by: SCHMERTZLER MICHAEL 6.2%
6/17 PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 5.9%
3/18 Form SEC STAFF LETTER PTC THERAPEUTICS, INC. 5.7%
10/2 Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress 5.6%
3/30 PTC Therapeutics, Inc. (NASDAQ: PTCT) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 5.5%
4/17 PTC Therapeutics Announces New Leadership Appointments 4.8%
TOP News Decliners
3/16
PTC Therapeutics Announces Management Change
-19.5%
3/11 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -11.4%
9/17 PTC Therapeutics Announces Proposed Public Offering of Common Stock -11.3%
4/29 PTC Therapeutics Q1 2020 Earnings Preview [Seeking Alpha] -9.4%
3/2 Form 8-K PTC THERAPEUTICS, INC. For: Mar 02 -5.8%
4/30 Q1/2020 3/31/2020 EPS -1.810 ZacksConsensus -1.080 ActVsEst (0.730) - Miss -5.7%
9/30 PTC Therapeutics, Inc. (NASDAQ: PTCT) was given a new $62.00 price target on by analysts at Citigroup Inc. They now have a "buy" rating on the stock. -4.7%
8/5 PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility -4.6%
1/13 PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference -4.2%
6/13 Form 8-K PTC THERAPEUTICS, INC. For: Jun 12 -4.1%
3/11 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -11.4%
9/17 PTC Therapeutics Announces Proposed Public Offering of Common Stock -11.3%
4/29 PTC Therapeutics Q1 2020 Earnings Preview [Seeking Alpha] -9.4%
3/2 Form 8-K PTC THERAPEUTICS, INC. For: Mar 02 -5.8%
4/30 Q1/2020 3/31/2020 EPS -1.810 ZacksConsensus -1.080 ActVsEst (0.730) - Miss -5.7%
9/30 PTC Therapeutics, Inc. (NASDAQ: PTCT) was given a new $62.00 price target on by analysts at Citigroup Inc. They now have a "buy" rating on the stock. -4.7%
8/5 PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility -4.6%
1/13 PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference -4.2%
6/13 Form 8-K PTC THERAPEUTICS, INC. For: Jun 12 -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: